ICER report demonstrates both the value and challenges in financing of weight loss medications.

This commentary examines the Institute for Clinical and Economic Review (ICER) report on GLP-1 receptor agonists (GLP-1 RAs) — specifically semaglutide and tirzepatide — for obesity management, evaluating both their clinical value and the challenges surrounding their financing. The authors note that while these agents demonstrate meaningful weight loss and cardiometabolic benefits and were deemed cost-effective versus lifestyle modification alone by ICER, even modest real-world uptake surpasses ICER's annual budget impact threshold, raising access concerns. The commentary highlights that real-world persistence with these medications is notably lower than in clinical trials, leading to frequent weight regain upon discontinuation and limiting anticipated long-term medical cost offsets. Evidence on medical spending is described as mixed: cost-offset signals appear primarily in patients with both obesity and diabetes using high-potency injectable agents, while obesity-only populations may see spending increases. To address these tensions, the authors recommend pairing drug coverage with lifestyle management programs, avoiding arbitrary treatment duration limits, applying targeted prior authorization, and exploring innovative payment models. Key limitations include the commentary format, reliance on heterogeneous real-world data, and lack of primary data collection.

Why this grade: This is a policy commentary synthesizing existing ICER findings and real-world evidence rather than presenting original experimental or observational data, limiting its independent evidentiary weight.